Skip to content

Evaluation of Antimicrobial Efficacy and Postoperative Pain After Using Silver Nanoparticles and Chitosan Nanoparticles Against Enterococcus Faecalis and Candida Albicans Biofilm

Evaluation of Antimicrobial Efficacy and Postoperative Pain After Using Silver Nanoparticles and Chitosan Nanoparticles Against Enterococcus Faecalis and Candida Albicans Biofilm (An in Vitro - in Vivo Study)

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06172023
Enrollment
78
Registered
2023-12-15
Start date
2020-01-01
Completion date
2023-03-01
Last updated
2023-12-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endodontic Disease

Brief summary

Silver nanoparticles possess unique physicochemical and biological properties in addition to their antibacterial capabilities. Similarly, zinc oxide nanoparticles have demonstrated antibacterial effects against a wide range of bacteria, including heat and pressure resistant spores. Given these characteristics, it would be valuable to evaluate and compare a new irrigation solution containing nanosilver and nanozinc-oxide particles with sodium hypochlorite. Furthermore, Chitosan Nanoparticles are expected to exhibit enhanced antibacterial activity compared to regular-sized Chitosan due to their ability to penetrate and disrupt microbial cell membranes. Consequently, the current study aims to assess and compare the antibacterial activity of Silver Nanoparticles and Chitosan Nanoparticles, as well as their impact on post-operative pain.

Interventions

Nanosilver irrigant solution

Chitosan nanoparticles irrigant solution

Sponsors

Minia University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
20 Years to 40 Years
Healthy volunteers
Yes

Inclusion criteria

* Medically stable healthy patients (category: American society of anesthesiologists class I). * The patient ranges in age from 20 to 40. * No sexual orientation * Necrotic pulp evaluated by thermal or electrical pulp testing. * Enough crown structure to provide adequate isolation. * One root and one canal. * Patients' desire to engage in this research. * Patients' comprehension of the visual analogue scale (VAS). * Patients' ability to sign informed consent.

Exclusion criteria

* Endodontic treatment for the tooth previously. * Teeth with poor conditions for using rubber dams. * Vital pulp tissue was observed throughout the treatment. * Patients who have a medical condition. * Teeth with open apices that are immature * Women who are pregnant or breastfeeding. * Psychologically disturbed patients. * Patients having a history of allergy to any of the research drugs were barred from participation. * A periodontally affected tooth with grade 2 or 3 mobility.

Design outcomes

Primary

MeasureTime frameDescription
Postoperative Pain Assessment6, 12, 24, 48, and 72 hoursEach patient was given a pain scale chart (VAS scale) before every endodontic operation to record his or her pain level. The VAS is a 10-point scale with values ranging from 0 to 10, with 0 representing No pain, (1-3) representing mild pain, (4-6) representing moderate pain, and (7-10) representing worst imaginable pain. At 6, 12, 24, 48, and 72 hours, each patient was instructed to use the VAS scale (0-10) to rate the presence and severity of discomfort after obturation.

Secondary

MeasureTime frameDescription
Antimicrobial Activity Assessment1 hour, 24 hours, 7 days, and 30 daysA sterile paper point was placed in each root canal to a level roughly 1 mm short of the apex, depending on working length radiographs, to get a sample from the root canal. The samples were suspended in a suspension of 25 microliters, which was pipetted onto a BHI agar plate. The colonies were counted using a Reichert-Jung colony counter after 1 hour, 24 hours, 7 days, and 30 days of incubation at 37oC in an anaerobic jar.

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026